Clinical Talks: Writing the Future
October 21 @ 17:00 – 17:30 CEST
Writing the Future
On October 21, Dr. Emily Leproust will talk about her mission with co-founding Twist Bioscience, and how their revolutionary oligosynthesis plattform is writing the future with DNA.
Twist Bioscience’s innovative silicon-based DNA Synthesis Platform is empowering our customers to realise their research goals faster. Twist offers DNA synthesis at an unmatched scale and price point, without compromising on precision or quality. Here we discuss how DNA synthesis at scale can make traditional molecular biology approaches redundant in labs working with plasmid vectors; can power massive, explicit diversity in CRISPR and antibody variant libraries; and can underpin NGS Target Enrichment Solutions with exceptional performance and unmatched speed in customisation. We’ll look at how these tools are helping drive innovation in a variety of research and application areas including cancer research, drug discovery, infectious disease and even data storage.
As an early pioneer in the high-throughput synthesis and sequencing of DNA, Dr. Leproust is disrupting markets to enable the exponential growth of DNA-based applications including chemicals/materials, diagnostics, therapeutics, food and digital data storage. In 2020, BIO presented her with the Rosalind Franklin Award for Leadership. Foreign Policy named her one of their 100 Leading Global Thinkers and Fast Company named her one of the Most Creative People in Business. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team. Dr. Leproust designed and developed multiple commercial synthesis platforms to streamline microarray manufacturing and fabrication. She serves on the Board of Directors of CM Life Sciences and is a co-founder of Petri, an accelerator for start-ups at the forefront of engineering and biology. Dr. Leproust has published over 30 peer-reviewed papers – many on applications of synthetic DNA, and is the author of numerous patents. She earned her Ph.D. in Organic Chemistry from University of Houston and her M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry.
Season 5, will be held September until December 2021 with scheduled Talks, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
After our recent planning hiatus, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting, innovative, and enlightening season. This season will focus on sustainable innovations within Life Sciences, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations.